As of 2026-05-29, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -2.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 139.17 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -47.32 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 3.4x - 5.1x | 4.2x |
| Forward P/E multiples | 3.4x - 5.2x | 4.3x |
| Fair Price | (1.68) - (2.51) | (2.10) |
| Upside | -208.7% - -263.0% | -236.0% |
| Date | EV/EBITDA |
| 2026-05-28 | -2.87 |
| 2026-05-27 | -2.94 |
| 2026-05-26 | -2.96 |
| 2026-05-25 | -3.08 |
| 2026-05-22 | -3.14 |
| 2026-05-21 | -3.45 |
| 2026-05-20 | -3.77 |
| 2026-05-19 | -3.47 |
| 2026-05-18 | -3.75 |
| 2026-05-15 | -3.33 |
| 2026-05-14 | -3.18 |
| 2026-05-13 | -2.32 |
| 2026-05-12 | -2.36 |
| 2026-05-11 | -2.39 |
| 2026-05-08 | -2.37 |
| 2026-05-07 | -2.38 |
| 2026-05-06 | -2.40 |
| 2026-05-05 | -2.32 |
| 2026-05-04 | -2.35 |
| 2026-04-30 | -2.26 |
| 2026-04-29 | -2.25 |
| 2026-04-28 | -2.22 |
| 2026-04-27 | -2.18 |
| 2026-04-24 | -2.10 |
| 2026-04-23 | -2.17 |
| 2026-04-22 | -2.22 |
| 2026-04-21 | -2.38 |
| 2026-04-20 | -2.46 |
| 2026-04-17 | -2.61 |
| 2026-04-16 | -2.56 |
| 2026-04-15 | -2.68 |
| 2026-04-14 | -2.58 |
| 2026-04-13 | -2.26 |
| 2026-04-10 | -2.19 |
| 2026-04-09 | -2.20 |
| 2026-04-08 | -2.25 |
| 2026-04-07 | -2.07 |
| 2026-04-02 | -2.19 |
| 2026-04-01 | -2.11 |
| 2026-03-31 | -1.98 |
| 2026-03-30 | -2.02 |
| 2026-03-27 | -2.06 |
| 2026-03-26 | -2.03 |
| 2026-03-25 | -2.17 |
| 2026-03-24 | -2.12 |
| 2026-03-23 | -2.20 |
| 2026-03-20 | -2.01 |
| 2026-03-19 | -2.17 |
| 2026-03-18 | -2.22 |
| 2026-03-17 | -2.20 |